



Bioethics

ISSN: 2989-5448 (Online)

Publisher: Tomorrow's Research Publications (TRP)

An International Peer-Reviewed Open Access Journal

Perspective

The Moral Case for and Against Compensated Egg Donation

Hanna Gallagher^{1*}, Ingrid Zielinska² and Bence Nowicki³

¹Institute for Health Policy and Ethics, Baltic Institute of Medical Humanities, Sweden

²Center for Medical Ethics and Law, Baltic Institute of Medical Humanities, Sweden

³Center for Medical Ethics and Law, Loire University Center for Clinical Ethics, France

ABSTRACT

Compensated oocyte donation sits at the intersection of two well-established but conflicting ethical intuitions: that competent adults may be paid for burdensome, risky labor, and that the human body and its reproductive material should not be treated as market commodities.

This perspective sets out the strongest versions of both the autonomy-and-fair-labor case for compensation and the commodification-and-exploitation case against it, drawing on the reproductive ethics and empirical donor-experience literature.

We examine the evidence on donor health risk and informed consent, which remains thinner than either side's arguments generally assume, and compare three regulatory approaches now in use: market-rate compensation, capped or state-set compensation, and altruism-only reimbursement.

None of the three models fully reconciles fair treatment of donors with protection against undue inducement and structural inequity in who supplies eggs.

We conclude that a defensible policy likely requires compensation that is decoupled from donor traits, combined with a substantially stronger long-term evidence base on donor health outcomes than currently exists.

Keywords: egg donation; oocyte donor compensation; commodification; informed consent; reproductive ethics

Citation: Gallagher H, Zielinska I and Nowicki B (2026) The Moral Case for and Against Compensated Egg Donation. *Bioethics*. 1(2):01-05.

Corresponding Author: Hanna Gallagher

E-mail Address: h.gallagher@bimh.se

Article History: Received 02 June 2026 | Accepted 05 September 2026 | Published 05 December 2026

Copyright: © 2026 Hanna Gallagher, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (<https://creativecommons.org/licenses/by/4.0/>).

INTRODUCTION

A woman who answers a fertility clinic's advertisement for egg donors is, depending on which side of a decades-old argument one finds persuasive, either exercising ordinary bodily autonomy for fair pay or

being drawn by money into a medical procedure whose risks she is poorly positioned to weigh. Both descriptions can be true of the same transaction, which is part of why compensated oocyte donation has remained one of the more stubbornly unresolved

questions in reproductive ethics even as the underlying technology has matured [1]. Unlike sperm donation, egg retrieval requires weeks of hormonal stimulation, a minor surgical procedure under sedation, and exposure to risks -- most notably ovarian hyperstimulation syndrome -- that fall on the donor alone, while the resulting oocytes benefit someone else entirely [2]. That asymmetry between who bears the burden and who receives the benefit is the seed of nearly every argument surveyed below.

Anthropologists who have studied donor recruitment on the ground describe an industry that has grown considerably more sophisticated since oocyte cryopreservation matured, with agencies now operating across borders and marketing directly to both intended parents and prospective donors in ways that blur the line between a medical service and a consumer product [3]. Jurisdictions have not converged on an answer. The United States permits market-rate compensation privately negotiated between clinics, agencies, and donors, with amounts that in some advertisements run well into five figures; most of Western Europe restricts payment to reimbursement of documented expenses and treats anything beyond that as commercialization of the body; and a smaller group of countries, including Israel, has opted for a state-set, capped payment that tries to occupy a middle position [4]. This is not a case where more data will settle the disagreement, because the competing positions rest on different starting premises about what a payment does to the moral character of the act it accompanies. This paper sets out the strongest version of the case for compensation, the strongest version of the case against it, and the empirical literature on donor health and consent that any defensible policy position has to accommodate.

THE CASE FOR COMPENSATION: AUTONOMY, LABOR, AND FAIR TREATMENT

The argument for paying egg donors ordinarily begins from a liberal premise: competent adults may consent to bear physical risk in exchange for money in countless other contexts -- manual labor, contact sports, clinical drug trials -- and it is not obvious why oocyte retrieval should be singled out for prohibition when comparably risky activities are not [5]. On this view, egg donation involves real time, real physical burden, and real risk, and treating it as something that must be given away rather than sold both undervalues the donor's contribution and imposes a moral judgment on her that the law does not impose on people who sell other forms of bodily labor. Refusing compensation, on this reading, does not eliminate the market in eggs; it merely ensures that the people supplying it are paid nothing for supplying it.

A related argument treats altruism-only policies as a kind of unfunded mandate. Countries that restrict payment to expense reimbursement have generally not

seen large volunteer donor pools materialize to replace commercial recruitment; instead they have seen persistent shortages, long waiting lists, and patients traveling abroad to jurisdictions where compensation is legal, a pattern documented across cross-border reproductive care more broadly [6]. Proponents of compensation argue that this outcome is itself an ethical cost worth weighing: an altruism-only rule that fails to produce enough altruistic donors does not abolish the underlying inequity, it exports it to countries with weaker regulatory oversight. Fair-market advocates also note that clinics, agencies, physicians, and, in the case of donations to stem-cell research, sometimes the researchers themselves, are all compensated for their part in the transaction; only the person undergoing the procedure is expected to act purely from altruism [7].

Empirical work on donor experience lends some support to the autonomy framing, at least for donors recruited through well-run programs. A study of women donating to a Dutch oocyte cryopreservation bank found that most reported the decision as freely made and reported no loss of self-esteem or sense of coercion associated with donating, which cuts against the assumption that payment or the donation process itself is inherently degrading to the women who choose it [8]. Advocates of compensation read findings like this as evidence that the objection to payment rests more on discomfort with the idea of a market in reproductive tissue than on demonstrated harm to the people actually participating in it.

THE CASE AGAINST: COMMODIFICATION, UNDUE INDUCEMENT, AND EXPLOITATION

The opposing position does not typically deny that donors can consent competently; it argues instead that payment changes what is being consented to, and for the worse. The commodification objection holds that attaching a price to human oocytes treats a component of reproduction, and by extension the body from which it is extracted, as a market good, which is a status many bioethicists think human biological material should never hold regardless of how willingly it is sold [9]. This is not primarily a claim about donor welfare; it is a claim about what a society expresses about the value of reproductive material and female bodies more generally when it allows both to be bought and sold like other commodities.

The undue-inducement objection is narrower and more directly about donor welfare: it holds that a large enough payment can distort a person's judgment about risk, leading her to consent to a procedure she would decline, or would scrutinize more carefully, at a lower price [10]. This is distinct from ordinary financial incentive, which exists in any paid activity; the concern is specifically that need-driven decision-making under the pressure of a large payment is not the same as autonomous decision-making under conditions of genuine freedom to refuse. Because compensation in

many US markets scales with donor characteristics such as education, ethnicity, and physical appearance that recipients find desirable, critics argue that the payment structure itself signals a market in traits rather than a fee for time and risk, sharpening rather than easing the commodification concern [2].

A third strand of the critique is structural rather than individual: it asks who actually supplies eggs under compensated systems, and finds that donor pools skew toward younger women with fewer economic alternatives, a pattern researchers studying cross-border and domestic donation markets have described as an inequality of who bears reproductive risk for whom [11]. Recruitment materials compound this concern when they combine appeals to altruism with prominent dollar figures and short application timelines, a combination one study of advertising language found could function as a form of low-grade coercion even without any single advertisement crossing an obvious ethical line on its own [12]. None of these authors argue that every compensated donor is exploited; the claim is that a compensation structure calibrated to donor traits and advertised in ways that emphasize speed and payment predictably produces conditions under which exploitation becomes more, not less, likely.

HEALTH RISKS AND THE LIMITS OF INFORMED CONSENT

Underlying both positions is a factual question that neither side disputes but that complicates each of their arguments: how much do egg donors actually know about the risks they are accepting, and how well is that risk actually characterized in the first place? Ovarian hyperstimulation syndrome is the acute risk most commonly disclosed to prospective donors, but the longer-term picture is thinner than consent documents sometimes imply. A registry-based study following recipients found measurable effects of donor stimulation protocols on outcomes, underscoring that stimulation is not a risk-free intervention even from the recipient's side of the transaction [13]. On the donor's side, a widely cited call for better follow-up argued that no large, long-term study has adequately tracked breast cancer incidence among women who underwent repeated ovarian stimulation as young donors, meaning that donors are, in a meaningful sense, consenting to an unknown rather than a known and quantified risk [14]. A retrospective survey of American donors similarly found gaps in donors' recollection and understanding of the medical and psychosocial risks they had been told about, months or years after donating [15].


Table 1 sets out how the three broad regulatory approaches -- market-rate compensation, capped compensation, and altruism-only with expense reimbursement -- differ on the dimensions this section and the two before it have raised: donor payment, the strength of the commodification objection each invites,

and the associated undue-inducement risk. Figure 1 places the same three models on a schematic low/medium/high comparison across donor autonomy in negotiating terms and the exploitation risk critics associate with each; it is illustrative rather than derived from a single quantitative study, since no dataset directly scores "exploitation risk" on a numeric scale, but it captures the trade-off the literature describes reasonably well. If informed consent is to do the moral work that compensation's defenders ask of it -- transforming what would otherwise be a coercive-looking transaction into a genuinely autonomous one -- it has to rest on risk disclosures that are actually complete, which the follow-up literature suggests is not yet reliably the case for any of the three models.

Table 1. Three regulatory approaches to oocyte donor compensation, compared by payment structure and the main ethical objection each invites.

Model	Payment structure	Main commodification concern	Main undue-inducement concern
Market-rate compensation (e.g. USA)	Privately negotiated fee, often scaled to donor traits	Treats reproductive tissue and donor traits as priced goods	Highest -- large, trait-linked sums may override risk deliberation
Capped/state-set compensation (e.g. Israel)	Fixed payment set by law or regulator, not trait-linked	Reduced but not eliminated -- payment still attached to the tissue	Moderate -- inducement is bounded but not removed
Altruism-only with expense reimbursement (much of Western Europe)	No payment beyond documented travel/medical expenses	Lowest in principle -- donation framed as gift, not sale	Low direct inducement, but shortages can push demand to less-regulated markets abroad

Figure 1. Schematic, illustrative comparison of donor bargaining autonomy and critics' associated exploitation-risk concern across the three regulatory models discussed in this review. Positions are qualitative summaries of the arguments surveyed in the text, not measurements from a single empirical study.



Reimbursement-based systems are not immune to their own version of this problem. Even a policy restricted to travel and lodging expenses requires

someone to decide what counts as a legitimate expense and what shades into disguised payment, a line one early ethical analysis of expense reimbursement found was harder to draw cleanly in practice than in principle [16]. And a joint task force examining oocyte donation for non-reproductive purposes, such as stem-cell derivation, concluded that the ethical case for donor payment is, if anything, weaker in that context, since the donor receives no share in whatever therapeutic or commercial value the resulting cell lines eventually generate [17].

REGULATORY RESPONSES AND THE LIMITS OF LITIGATION

The most consequential recent shift in US practice came not from legislation but from a 2016 antitrust settlement in which the American Society for Reproductive Medicine agreed to remove its guideline capping donor compensation, after donors argued the cap functioned as unlawful price-fixing; commentators have since debated whether the settlement improved donor welfare by letting compensation rise to reflect actual burden, or simply removed the last soft constraint on a market already tilted toward recipients and intermediaries [18]. That the resolution came through antitrust law rather than a bioethics body is itself revealing: it suggests that in the absence of professional consensus on where the line between fair pay and undue inducement lies, market and legal forces will draw the line instead, on criteria that have nothing to do with donor welfare.

Countries that have chosen a capped or state-administered compensation model, by contrast, have tried to preserve some of the autonomy argument's force -- donors are paid, and the payment is not treated as inherently corrupting -- while limiting the size of the inducement and, in principle, decoupling payment from donor traits recipients might select for [4]. Whether a cap actually prevents inducement-driven decision-making, as opposed to simply lowering the price at which it might occur, remains an open empirical question that the literature reviewed here has not settled, and it is unlikely to be settled by philosophical argument alone.

CONCLUSION

Neither position surveyed here wins outright, because they are not fully answering the same question. The autonomy argument is strongest as a rebuttal to paternalistic objections that treat any payment as automatically corrupting a competent adult's choice; it is weaker as a response to the structural critique that compensation, particularly compensation scaled to donor traits, systematically draws disproportionately from women with fewer alternatives and predictably outpaces what the current evidence base can tell those women about long-term risk. The commodification and exploitation arguments are strongest as a account of why compensation should not be unlimited or

trait-linked; they are weaker as a blanket case against payment altogether, since altruism-only regimes have not eliminated the underlying market so much as displaced it across borders with less oversight, not more.

A defensible policy position likely has to hold several of these conclusions at once: some compensation for time, discomfort, and risk is owed to donors as a matter of basic fairness, that compensation should be structured to avoid scaling with traits recipients select for, and disclosure of long-term risk needs a much stronger evidence base than currently exists before informed consent can bear the moral weight either side of this debate wants to place on it. None of the three regulatory models reviewed here fully achieves that combination yet, which is less a failure of any one jurisdiction than a sign that the underlying ethical tension has not actually been resolved, only managed differently in different places.

DECLARATIONS

Acknowledgements

The authors thank colleagues at their respective institutes for helpful conversations that sharpened the arguments developed in this paper.

Funding

This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

H.G. conceived the paper and drafted the introduction and the sections on the case for and against compensation; I.Z. drafted the sections on health risks, informed consent, and regulatory responses and coordinated revisions; B.N. contributed the comparative regulatory analysis, prepared the table and figure, and reviewed and edited the full manuscript. All authors approved the final version.

Ethics Statement

This article is a literature review and policy analysis; it did not involve new research with human participants or animals and did not require ethics committee approval.

Data Availability

No new data were generated for this article. All sources discussed are publicly available published works cited in the reference list.

REFERENCES

1. Klein JU, Sauer MV (2010) Ethics in egg donation: past, present, and future. *Seminars in Reproductive Medicine*, PMID:20683796.

2. Bayefsky MJ, DeCherney AH, Berkman BE (2016) Compensation for egg donation: a zero-sum game. *Fertility and Sterility*, PMID:26854609.
3. Tober D, Pavone V, Lafuente-Funes S, Konvalinka N (2023) Eggonomics: vitrification and bioeconomies of egg donation in the United States and Spain. *Medical Anthropology Quarterly*, PMID:37229598.
4. Gruenbaum BF, Pinchover ZS, Lunenfeld E, Jotkowitz A (2011) Ovum donation: examining the new Israeli law. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, PMID:21824713.
5. Steinbock B (2004) Payment for egg donation and surrogacy. *Mount Sinai Journal of Medicine*, PMID:15365592.
6. Neri M, Turillazzi E, Pascale N, Riezzo I, Pomara C (2016) Egg production and donation: a new frontier in the global landscape of cross-border reproductive care: ethical concerns. *Current Pharmaceutical Biotechnology*, PMID:26775650.
7. Baylis F, McLeod C (2007) The stem cell debate continues: the buying and selling of eggs for research. *Journal of Medical Ethics*, PMID:18055905.
8. Bakker MR, Maas J, Bekker MH, Bredenoord AL, Fauser BC, Bos AM (2017) Autonomy and self-esteem of women who donate to an oocyte cryopreservation bank in the Netherlands. *Reproductive Biomedicine Online*, PMID:28579040.
9. Heng BC (2006) Advances in oocyte cryopreservation technology will eventually blur the ethical and moral boundaries between compensated egg sharing and commercialized oocyte donation. *Reproductive Biomedicine Online*, PMID:16569309.
10. Sutton A (2018) Is payment for egg donation an undue inducement? *New Bioethics*, PMID:30230422.
11. Nahman M (2011) Reverse traffic: intersecting inequalities in human egg donation. *Reproductive Biomedicine Online*, PMID:21945267.
12. Lake R, Berzansky I, Lanes A, Srouji S, Ginsburg E, Insogna I (2024) Informed consent and coercion in recruitment advertisements for oocyte donors. *BMC Women's Health*, PMID:39300511.
13. Hipp HS, Gaskins AJ, Nagy ZP, Capelouto SM, Shapiro DB, Spencer JB (2020) Effect of oocyte donor stimulation on recipient outcomes: data from a US national donor oocyte bank. *Human Reproduction*, PMID:32142582.
14. Schneider J, Lahl J, Kramer W (2017) Long-term breast cancer risk following ovarian stimulation in young egg donors: a call for follow-up, research and informed consent. *Reproductive Biomedicine Online*, PMID:28473127.
15. Kramer W, Schneider J, Schultz N (2009) US oocyte donors: a retrospective study of medical and psychosocial issues. *Human Reproduction*, PMID:19729378.
16. Heng BC (2005) Ethical issues in paying for long-distance travel and accommodation expenses of oocyte donors. *Reproductive Biomedicine Online*, PMID:16409701.
17. ESHRE Task Force on Ethics and Law; Pennings G, de Wert G, Shenfield F, Cohen J, Tarlatzis B, Devroey P (2007) ESHRE Task Force on Ethics and Law 12: oocyte donation for non-reproductive purposes. *Human Reproduction*, PMID:17347168.
18. Klitzman RL, Sauer MV (2015) Kamakahi vs ASRM and the future of compensation for human eggs. *American Journal of Obstetrics and Gynecology*, PMID:25816784.